| Primary |
| Product Used For Unknown Indication |
43.3% |
| Drug Use For Unknown Indication |
24.1% |
| Epilepsy |
10.0% |
| Drug Exposure During Pregnancy |
3.7% |
| Bipolar Disorder |
3.3% |
| Maternal Exposure Timing Unspecified |
2.6% |
| Convulsion |
1.5% |
| Grand Mal Convulsion |
1.5% |
| Thrombosis Prophylaxis |
1.5% |
| Chronic Obstructive Pulmonary Disease |
1.1% |
| Dermatitis |
1.1% |
| Tachycardia Paroxysmal |
1.1% |
| Asthma |
0.7% |
| Depression |
0.7% |
| Hereditary Disorder |
0.7% |
| Hypersensitivity |
0.7% |
| Meningitis |
0.7% |
| Status Epilepticus |
0.7% |
| Bipolar I Disorder |
0.4% |
| Chemotherapy |
0.4% |
|
| Transaminases Increased |
8.2% |
| Tremor |
8.2% |
| Vomiting |
8.2% |
| Epilepsy |
6.1% |
| Metabolic Acidosis |
6.1% |
| Weight Increased |
6.1% |
| Cell-mediated Immune Deficiency |
4.1% |
| Convulsion |
4.1% |
| Drug Exposure During Pregnancy |
4.1% |
| Drug Ineffective |
4.1% |
| Drug Interaction |
4.1% |
| Fatigue |
4.1% |
| Pancreatitis Acute |
4.1% |
| Performance Status Decreased |
4.1% |
| Pseudodementia |
4.1% |
| Renal Failure |
4.1% |
| Speech Disorder |
4.1% |
| Speech Disorder Developmental |
4.1% |
| Talipes |
4.1% |
| Weight Fluctuation |
4.1% |
|
| Secondary |
| Drug Use For Unknown Indication |
46.8% |
| Product Used For Unknown Indication |
21.3% |
| Epilepsy |
6.4% |
| Infection |
4.3% |
| Ill-defined Disorder |
4.0% |
| Chronic Obstructive Pulmonary Disease |
2.0% |
| Supraventricular Tachycardia |
2.0% |
| Dermatitis |
1.8% |
| Thrombosis Prophylaxis |
1.7% |
| Bipolar Disorder |
1.4% |
| Grand Mal Convulsion |
1.4% |
| Gout |
1.2% |
| Schizoaffective Disorder |
1.2% |
| Conjunctivitis |
0.8% |
| Convulsion |
0.8% |
| Nausea |
0.6% |
| Pruritus |
0.6% |
| Schizophrenia, Residual Type |
0.6% |
| Sleep Disorder |
0.6% |
| Tachycardia Paroxysmal |
0.6% |
|
| Vomiting |
20.5% |
| Hyponatraemia |
11.1% |
| Therapeutic Agent Toxicity |
10.3% |
| Renal Failure |
6.8% |
| Tremor |
6.0% |
| Restlessness |
5.1% |
| Thrombocytopenia |
5.1% |
| Transaminases Increased |
4.3% |
| Drug Ineffective |
3.4% |
| Speech Disorder |
3.4% |
| Suicide Attempt |
3.4% |
| Toxic Epidermal Necrolysis |
3.4% |
| Drug Interaction |
2.6% |
| Neutropenia |
2.6% |
| Pleurothotonus |
2.6% |
| Tachycardia |
2.6% |
| Altered State Of Consciousness |
1.7% |
| Hepatic Enzyme Increased |
1.7% |
| Hirsutism |
1.7% |
| Hypotension |
1.7% |
|
| Concomitant |
| Drug Use For Unknown Indication |
18.6% |
| Epilepsy |
12.2% |
| Product Used For Unknown Indication |
11.9% |
| Hypertension |
8.7% |
| Schizoaffective Disorder |
8.0% |
| Bipolar Disorder |
6.1% |
| Bipolar I Disorder |
5.4% |
| Mania |
3.2% |
| Convulsion |
2.9% |
| Schizophrenia |
2.9% |
| Anaemia |
2.6% |
| Depression |
2.6% |
| Gout |
2.6% |
| Psychotic Disorder |
2.2% |
| Blood Corticotrophin Decreased |
1.9% |
| Blood Follicle Stimulating Hormone Decreased |
1.9% |
| Blood Luteinising Hormone Decreased |
1.9% |
| Hypogonadism Female |
1.9% |
| Grand Mal Convulsion |
1.3% |
| Partial Seizures |
1.3% |
|
| Weight Increased |
16.0% |
| Urinary Tract Infection |
10.0% |
| Weight Decreased |
9.0% |
| Polyneuropathy |
8.0% |
| Sensory Loss |
7.0% |
| Parkinsonism |
6.0% |
| Acute Hepatic Failure |
4.0% |
| Dizziness |
4.0% |
| Red Blood Cell Count Decreased |
4.0% |
| Ventricular Extrasystoles |
4.0% |
| Vomiting |
4.0% |
| Hyponatraemia |
3.0% |
| Supraventricular Extrasystoles |
3.0% |
| Tachyarrhythmia |
3.0% |
| Urticaria |
3.0% |
| White Blood Cell Count Decreased |
3.0% |
| White Blood Cell Count Increased |
3.0% |
| Drug Screen Positive |
2.0% |
| Immunodeficiency |
2.0% |
| Neutrophil Count Decreased |
2.0% |
|
| Interacting |
| Drug Use For Unknown Indication |
58.9% |
| Product Used For Unknown Indication |
21.5% |
| Mania |
4.3% |
| Pneumonia |
4.3% |
| Schizoaffective Disorder |
4.3% |
| Epilepsy |
2.4% |
| Prophylaxis |
1.9% |
| Bipolar I Disorder |
1.0% |
| Breast Cancer |
0.5% |
| Crohn's Disease |
0.5% |
| H1n1 Influenza |
0.5% |
|
| Encephalopathy |
22.2% |
| Renal Failure |
22.2% |
| Right Atrial Dilatation |
13.9% |
| Drug Interaction |
11.1% |
| Grand Mal Convulsion |
5.6% |
| Stasis Dermatitis |
5.6% |
| Thrombosis |
5.6% |
| Epilepsy |
2.8% |
| Galactorrhoea |
2.8% |
| Musculoskeletal Pain |
2.8% |
| Speech Disorder |
2.8% |
| Thrombocytopenia |
2.8% |
|
